Company description

Incyte Corporation, with the ticker INCY, is a biopharmaceutical company based in the United States. Founded in 2002, the company's main focus is on the research and development of innovative medicines to treat serious and life-threatening diseases, particularly in the fields of oncology and inflammatory disorders. Their portfolio includes numerous approved and investigational drugs, such as Jakafi, a treatment for blood cancer, and baricitinib, a treatment for rheumatoid arthritis. With a strong commitment to scientific research and development, Incyte has established partnerships with various global pharmaceutical companies to advance their drug candidates. The company's mission is to improve the lives of patients by constantly striving to bring effective and innovative treatments to the market. Along with their dedication to medical advancements, Incyte also places great importance on promoting a diverse and inclusive workplace culture, with a strong emphasis on ethical and responsible business practices. Despite the challenges faced by the biopharmaceutical industry, Incyte continues to demonstrate consistent growth and remains a leader in the field, with a strong track record of delivering positive results for patients and stakeholders alike.